skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Luteal phase support in assisted reproductive technology treatment: focus on Endometrin® (progesterone) vaginal insert

Review

(2316) Views  (867) Full article downloads

Authors: Jerome H Check

Published Date May 2009 Volume 2009:5 Pages 403 - 407
DOI: http://dx.doi.org/10.2147/TCRM.S4192

Jerome H Check

The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Camden, New Jersey, USA

Abstract: Supplementation of progesterone in the luteal phase and continuance of progesterone therapy during the first trimester has been found in several studies to have benefits in promoting fertility, preventing miscarriages and even preventing pre-term labor. Though it can be administered orally, intramuscularly or even sublingually, a very effective route with fewer side effects can be achieved by an intravaginal route. The first vaginal preparations were not made commercially but were compounded by pharmacies. This had the disadvantage of lack of control by the Food and Drug Administration (FDA) ensuring efficacy of the preparations. Furthermore there was a lack of precise dosing leading to batch to batch variation. The first commercially approved vaginal progesterone preparation in the United States was a vaginal gel which has proven very effective. The main side effect was accumulation of a buildup of the vaginal gel sometimes leading to irritation. Natural micronized progesterone for vaginal administration with the brand name of Utrogestan A® had been approved even before the gel in certain European countries. Endometrin® vaginal tablets are the newest natural progesterone approved by the FDA. Comparisons to the vaginal gel and to intramuscular progesterone have shown similar efficacy especially in studies following controlled ovarian hyperstimulation and oocyte egg retrieval and embryo transfer. Larger studies are needed to compare side effects.

Keywords: progesterone vaginal tablets, luteal phase, miscarriage, pregnancy rates








Readers of this article also read:

Nonsurgical treatment of male infertility: specific and empiric therapy
Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The benefits and risks of testosterone replacement therapy: a review
Guaifenesin and increased sperm motility: a preliminary case report
Treatment options for polycystic ovary syndrome
Differences in maintenance of mean blood glucose (BG) and their association with response to “recognizing hunger”
Effect of Helicobacter pylori infection on pregnancy rates and early pregnancy loss after intracytoplasmic sperm injection
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection